


CLINICAL TRIAL

GEMINI - NCT03507686

Research



An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

Rare Eye Disease concerned by the trial :
Choroideremia

Status of the trial : Active, not recruiting
Orphan drug recognition : Yes

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date : 01/02/2018



Inclusion closing date (previsional) : 01/02/2019

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Center for Ophthalmic Research, University Hospital of Tübingen

Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

[Contact details](#)



Principal investigator name :

Prof. Dr. Dr. Dominik Fischer




Other investigators :

Prof. Dr. med. Karl Ulrich Bartz-Schmidt
Dr. Katarina Stingl

University Hospital of Tübingen

Tübingen, Germany



Funder type : Drug company - Industry

[More informations](#)